2021 Patient Education Events & Global Health Repurposing Awards

Announcing our virtual Fall 2021 patient education events!

Real World Data Through a Patient’s Lens

October 12, 2021 from 1:00pm to 2:30pm ET

A conversation on Real World Data (RWD) and case reports from clinicians and researchers. This patient education event will focus on what RWD means, the importance of RWD in clinical decision making, RWD and off-label usage by doctors and patients, the role patients and caregivers can play in collecting RWD, and how patients and caregivers can utilize RWD to impact their own healthcare. Speakers will provide the perspectives of industry, payers, clinicians, nonprofits and the patient voice.

Moderator: Kenneth Quinto MD, MPH, Senior Medical Advisor for Real World Evidence Analytics, Center for Drug Evaluation and Research, US FDA

Speakers:

Ryan Fischer, Chief Advocacy Officer, Parent Project Muscular Dystrophy

Mark Gallagher, MD, Cardiologist, St George’s Hospital NHS Trust, UK

Stacy L. Lloyd, MPH, Director, Digital Health & Operations, American Medical Association, and Board Certified Patient Advocate

Anita Stewart, MD, FAAP, JD, MPH, Medical Director, BCBS of Illinois

Diversity of Clinical Trial Researchers and Patients: A Repurposing Opportunity?

November 9, 2021 from 1:00pm to 2:45pm ET

A dialogue on the dual opportunities of clinical trial diversity to impact health disparities and/or improve minority leadership in scientific research. Topics include the importance of diversity in finding treatments for unsolved diseases, health disparities and the role of repurposed therapies in addressing them; community organizations’ role in clinical research diversity; and the need to reduce the NIH funding gap for underrepresented racial/ethnic minority researchers. Speakers will provide the perspectives of industry, research, clinicians, community organizations and the patient voice.

During the event, there will be a showcase of our ongoing clinical trials within our Diversity, Equity & Inclusion Community, including projects impacting health disparities and led by racial/ethnic minority and underserved scientists.

Moderator: RADM Richardae Araojo, PharmD, MS, Associate Commissioner for Minority Health, Director, Office of Minority Health and Health Equity, US Food & Drug Administration

Speakers:

Regina Greer-Smith, MPH, LFACHE, President, Health Research Associates

LaShell Robinson, MS, Director, Diversity & Inclusion in Clinical Trials, Takeda Pharmaceuticals

Karriem S. Watson, DHS, MS, MPH, Chief Engagement Officer, All of Us Research Program, National Institutes of Health

Showcase Presenters:

Mainga Hamaluba, MBChB, MRCPCH, MD, KEMRI Wellcome Trust Research Programme

David Meltzer, MD, PhD, University of Chicago

Tycel Phillips, MD, Michigan Medicine

Thank you for joining us for these virtual Fall 2021 patient education events to help honor our 2021 Patient Impact Award Recipients.

Patients and caregivers FREE thanks to our supporters and partners. Nonprofit attendees only $15 for one event or $25 for BOTH events. Industry attendees only $30 for one event or $45 for BOTH events.

After both of our patient education sessions, Cures Within Reach presented ReFRAME at Scripps Research / Calibr, CURE ID at the FDA and NCATS/NIH and Eli Lilly and Company with their 2021 Patient Impact Awards, recognizing each organization’s outstanding achievements in creating impact for patients by repurposing existing science and medicine.

During these patient-focused events, Cures Within Reach celebrated and honored:

ReFRAME at Calibr, Scripps Research’s drug discovery division, and the impact that its screening database is having on patients with neglected diseases as well as finding potential COVID-19 treatments. We celebrate Calibr’s commitment to the database’s ease of accessibility and the collaboration made possible through this technology, especially during the COVID-19 pandemic. Since ReFRAME’s launch, repurposed drugs such as clofazimine in cryptosporidiosis and auranofin in TB are impacting patients in clinical trials.

CURE ID, a tool that allows clinicians and researchers to share repurposing case reports as a means to identify drugs for further study in clinical trials. We celebrate the development and launch of CURE ID for infectious diseases and soon for other diseases as well. We especially recognize the enhancements the FDA and NCATS/NIH made to CURE ID to help assist in the COVID-19 response. CURE ID is an example of the government’s critical role in the repurposing ecosystem and the FDA and NIH’s long-time commitment to enhancing drug development for difficult-to-treat diseases.

Lilly’s ongoing commitment to improving the lives of patients with unmet medical needs. During the COVID-19 pandemic, this has been through its support of baricitinib, an existing rheumatoid arthritis medication, to treat certain hospitalized COVID-19 patients, among other initiatives. Baricitinib has been authorized for emergency use by the FDA in combination with remdesivir. In addition, Lilly has continued to test already approved therapies for new indications, including duloxetine for fibromyalgia and ramucirumab for various cancers after it was first approved for stomach cancer.